CN116236425A - Composition for scalp care after hair implantation, preparation method and application thereof - Google Patents
Composition for scalp care after hair implantation, preparation method and application thereof Download PDFInfo
- Publication number
- CN116236425A CN116236425A CN202111512463.2A CN202111512463A CN116236425A CN 116236425 A CN116236425 A CN 116236425A CN 202111512463 A CN202111512463 A CN 202111512463A CN 116236425 A CN116236425 A CN 116236425A
- Authority
- CN
- China
- Prior art keywords
- exemestane
- hyaluronate
- extract
- composition
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 210000004761 scalp Anatomy 0.000 title claims abstract description 66
- 210000004209 hair Anatomy 0.000 title claims abstract description 54
- 238000002513 implantation Methods 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 239000000284 extract Substances 0.000 claims description 115
- 239000000243 solution Substances 0.000 claims description 94
- 229920002674 hyaluronan Polymers 0.000 claims description 66
- 239000006166 lysate Substances 0.000 claims description 64
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 63
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 63
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 63
- 238000000855 fermentation Methods 0.000 claims description 63
- 230000004151 fermentation Effects 0.000 claims description 63
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 63
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 63
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims description 62
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 56
- 229940014041 hyaluronate Drugs 0.000 claims description 56
- 239000007921 spray Substances 0.000 claims description 56
- 229960003160 hyaluronic acid Drugs 0.000 claims description 51
- 239000000126 substance Substances 0.000 claims description 50
- 239000009670 cang er zi wan Substances 0.000 claims description 48
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 35
- -1 exemestane sodium salt Chemical class 0.000 claims description 35
- 229960000255 exemestane Drugs 0.000 claims description 33
- 210000003780 hair follicle Anatomy 0.000 claims description 21
- 239000000419 plant extract Substances 0.000 claims description 18
- 229940099552 hyaluronan Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 12
- 230000004083 survival effect Effects 0.000 claims description 12
- 240000002924 Platycladus orientalis Species 0.000 claims description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 10
- 229920001542 oligosaccharide Polymers 0.000 claims description 10
- 239000011591 potassium Substances 0.000 claims description 10
- 229910052700 potassium Inorganic materials 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 claims description 9
- 239000011777 magnesium Substances 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 241001506766 Xanthium Species 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 2
- 241001251949 Xanthium sibiricum Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 79
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 38
- 229920000053 polysorbate 80 Polymers 0.000 description 38
- 238000003756 stirring Methods 0.000 description 37
- 239000008215 water for injection Substances 0.000 description 27
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 16
- 108010011459 Exenatide Proteins 0.000 description 16
- 229960001519 exenatide Drugs 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 201000004384 Alopecia Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000008439 repair process Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 231100000360 alopecia Toxicity 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 206010016936 Folliculitis Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIIBBJKLKFTNQO-WHFBIAKZSA-N 5-hydroxyectoine Chemical group CC1=N[C@H](C(O)=O)[C@@H](O)CN1 KIIBBJKLKFTNQO-WHFBIAKZSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- ORUDEUCNYHCHPB-OUUBHVDSSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-tetradecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ORUDEUCNYHCHPB-OUUBHVDSSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000005874 Bifenthrin Substances 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012426 Dermal cyst Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000003377 Shepherdia canadensis Species 0.000 description 1
- 235000018324 Shepherdia canadensis Nutrition 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- OMFRMAHOUUJSGP-IRHGGOMRSA-N bifenthrin Chemical compound C1=CC=C(C=2C=CC=CC=2)C(C)=C1COC(=O)[C@@H]1[C@H](\C=C(/Cl)C(F)(F)F)C1(C)C OMFRMAHOUUJSGP-IRHGGOMRSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 239000004247 glycine and its sodium salt Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940095673 shampoo product Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229940029258 sodium glycinate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940039576 xanthium extract Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a composition for scalp care after hair implantation, a preparation method and application thereof.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a composition for scalp care after hair implantation, a preparation method and application thereof.
Background
The hair is used as an important part of the body, and has the functions of beautifying the instrument, protecting the scalp, reducing and avoiding external mechanical and chemical damage to tissues or reducing damage of ultraviolet rays to the scalp and tissues and organs in the scalp, and the like. The basis for the hair to be able to survive and grow normally is the hair follicle, which grows periodically, and thus the life of the hair is also periodic. Alopecia is a phenomenon of hair loss, is one of more common dermatological diseases, and is accompanied by a trend of younger people, as the work and life pressures of modern people are continuously increased, the influence of environmental factors is continuously increased in recent years. As the problem of hair loss becomes increasingly common, the need for hair growth by hair loss prevention is becoming far greater and urgent.
The hair transplantation is to cut the tissue around the hair follicle completely through a special instrument, separate from the scalp, and transplant the hair to a position where the hair is required to be prepared and the condition of catching the hair is provided. The hair transplantation is mainly used for treating male hormone alopecia, can be used for treating head cicatricial alopecia in addition to improving local hair coverage, and can also be used for treating hairline areas, eyebrow bows, eyelashes and the like through hair transplantation, so that the hair transplantation method is a long-term effective method for solving alopecia, and is increasingly popular with alopecia people. Common complications after the implantation include: hair loss in the transplanted area due to changes in the local microenvironment of the hair follicle, oedema, infection, and local vascular damage; local scar formation, excessive collection, local skin necrosis, etc., and complications such as folliculitis, punctate scar, etc. caused by hair loss, subcutaneous cyst, and implant embedding at the donor area.
At present, the nursing after hair implantation mainly adopts modes such as normal saline flushing and the like, has only a flushing function, can not repair damaged scalp and hair follicles after operation, and a patient washes hair by adopting a low-stimulation shampoo product after operation is restored to a certain extent, so that the problems of high irritation, easiness in residual chemical substances and the like exist, folliculitis is extremely easy to induce, the survival rate of hair follicles after hair implantation is influenced, the recovery of postoperative scalp functions is not facilitated, and no product for nursing scalp after hair implantation is temporarily available in the market.
The Chinese patent application CN110522698A discloses a scalp injury repair essence and a preparation method thereof, and relates to the field of scalp injury repair, wherein the essence comprises the following components in percentage by weight: 5-10% of glycerol, 5-10% of 1, 3-butanediol, 0.1-1% of glycyrrhizin, 0.1-0.5% of zinc gluconate, 1-5% of glycogen, 15-25% of active extract, 0.5-3% of beta-glucan, 0.05-1% of sodium hyaluronate, 0.1-1% of hydrolyzed collagen, 0.5-5% of compound amino acid, 0.05-1% of biotin, 0.01-1% of cupreotide and the balance of water. The scalp injury repair essence prepared by the raw material components can be used for repairing damaged scalp, relieving congestion, accelerating capillary tension of tissues around the skin, relieving edema, resisting local inflammation, accelerating wound healing, supplementing scalp nutrition, promoting skin regeneration, facilitating hair regeneration and the like.
The Chinese patent application CN110496084A discloses a cleaning shampoo for repairing scalp injury and a preparation method thereof, belongs to the field of shampoo and hair care products, and is prepared from the following raw materials in percentage by mass: 5-10% of cocoyl sodium glutamate, 5-10% of sodium lauryl glucose carboxylate, 2-5% of cocoyl sodium glycinate, 5-10% of cocoyl amidopropyl betaine, 2-5% of myristyl glucoside, 2-5% of sodium lauroyl sarcosine, 2-8% of soapberry fruit extract, 1-5% of andrographis paniculata extract, 1-5% of honeysuckle extract, 1-5% of rhizoma coptidis extract, 5-10% of glycerol and the balance of deionized water; the shampoo prepared by the preparation method disclosed by the invention can be used for avoiding damage to scalp during hair planting, shaping and the like, nourishing scalp skin, gently cleaning damaged scalp parts, and has no irritation to skin, no damage to hair and wide application prospect.
Disclosure of Invention
In order to solve the technical problem that the prior product cannot meet the defect of nursing of large-area damaged scalp and hair follicles after hair implantation, the invention provides a scalp nursing composition for hair implantation, which is mild and non-irritating, can quickly calm the red and swollen scalp after operation, promote scalp injury repair and improve the survival rate of hair follicles after hair implantation.
The composition can improve the survival rate of hair follicles, and has synergistic effects in anti-inflammatory, scalp injury repair promotion and the like.
The specific technical scheme of the invention is as follows:
1. a composition for scalp care after hair implantation comprising an exemestane species.
2. The composition according to item 1, wherein the ectoin-like substance is 0.05-5%, preferably 0.9-3.2% by mass of the composition.
3. The composition according to item 1 or 2, wherein the exemestane is exemestane and/or an exemestane derivative, preferably the exemestane derivative is hydroxy exemestane, exemestane sodium salt and/or exemestane potassium salt.
4. The composition according to any one of claims 1 to 3, wherein the composition further comprises a hyaluronic acid-based substance, preferably the hyaluronic acid-based substance is hyaluronic acid and/or hyaluronate, further preferably the hyaluronic acid and/or hyaluronate is 0.1-0.8%, preferably 0.3-0.6% by mass of the composition.
5. The composition according to item 4, wherein the hyaluronate is one or more selected from the group consisting of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate and calcium hyaluronate, preferably sodium hyaluronate.
6. The composition according to item 4 or 5, wherein the hyaluronan is a hyaluronan oligosaccharide, preferably the hyaluronan has a molecular weight of 2500-9500Da, preferably 4000-6000Da.
7. The composition according to any one of claims 1 to 6, wherein the composition further comprises a lysate of a fermentation product of saccharomyces cerevisiae, preferably 0.01-0.5%, preferably 0.1-0.3% by mass of the lysate of a fermentation product of saccharomyces cerevisiae, based on the mass percentage of the composition.
8. The composition according to any one of claims 1-7, wherein the composition further comprises a plant extract, preferably the plant extract is a cocklebur fruit extract and/or a biota orientalis leaf extract; further preferably, the fructus Xanthii extract is 0.5-2% and the folium Platycladi extract is 0.2% -1.8% by mass of the composition.
9. The composition according to any one of claims 1-8, wherein the composition further comprises a pharmaceutically acceptable adjuvant, preferably the pharmaceutically acceptable adjuvant is a surfactant.
10. A formulation for scalp care after hair implantation, the formulation being made from the starting materials of the composition of any one of claims 1-9.
11. The formulation according to item 10, wherein the formulation is in the form of a solution, spray, drop or lotion, preferably a spray.
12. A method of preparing a spray for post-hair-implantation scalp care comprising the steps of:
dissolving the exendin substance, optional hyaluronic acid substance and optional lysate of fermentation product of the two yeasts in water to obtain solution A;
adding an optional surfactant into the solution A to obtain a solution B;
adding the optional plant extract into solution B to obtain spray.
13. The method according to claim 12, wherein the exendin is exendin and/or an exendin derivative, preferably, the exendin derivative is hydroxy exendin, exendin sodium salt and/or exendin potassium salt, further preferably, the exendin is 0.05-5%, preferably 0.9-3.2% based on the mass percentage of the spray.
14. The method according to claim 12 or 13, wherein the hyaluronic acid-based substance is hyaluronic acid and/or hyaluronate, preferably, the hyaluronate is one or more selected from sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate and calcium hyaluronate, preferably sodium hyaluronate, further preferably, the hyaluronic acid and/or hyaluronate is 0.1 to 0.8%, preferably 0.3 to 0.6% by mass percentage in the spray.
15. The method according to any one of claims 12-14, wherein the hyaluronan is a hyaluronan oligosaccharide, preferably the hyaluronan has a molecular weight of 2500-9500Da, preferably 4000-6000Da.
16. The method according to any one of claims 12 to 15, wherein the lysate of the fermentation product of saccharomyces cerevisiae is 0.01-0.5%, preferably 0.1-0.3% by mass percentage in the spray.
17. The method of any one of claims 12-16, wherein the plant extract is a cocklebur fruit extract and/or a biota orientalis leaf extract; further preferably, the cocklebur fruit extract is 0.5-2% and the biota orientalis leaf extract is 0.2% -1.8% by mass percent of the spray.
18. The use of an exemestane in a scalp care product, preferably in a scalp care product after hair implantation, and more preferably in a scalp care product for improving the survival rate of hair follicles.
19. The use according to claim 18, wherein the ectoin is 0.05-5%, preferably 0.9-3.2% by mass of the scalp care product.
20. The use according to claim 18 or 19, wherein the exemestane is exemestane and/or an exemestane derivative, preferably the exemestane derivative is hydroxy exemestane, exemestane sodium salt and/or exemestane potassium salt.
21. A scalp care comprising the composition of any one of claims 1-9 or the formulation of any one of claims 10-11.
21. A scalp care product according to item 20 wherein the scalp care product further comprises an adjunct.
ADVANTAGEOUS EFFECTS OF INVENTION
The composition disclosed by the invention has the remarkable moisturizing and anti-inflammatory effects while promoting the rapid healing of damaged scalp wounds after hair implantation, reduces the incidence rate of folliculitis after hair implantation, and plays a role in synergy.
The composition disclosed by the invention has the advantages that the contained components are nontoxic and nonirritating, the blank of scalp care products after hair implantation is filled, the scalp is cleaned, the wound healing and anti-inflammatory effects are promoted, the hair follicle survival rate is improved, the incidence rate of folliculitis after hair implantation is reduced, the red swelling and itching after hair implantation are effectively relieved, the hair implantation success rate is improved, and the preparation prepared by the invention is convenient to use and does not cause secondary damage to damaged scalp.
Detailed Description
The present invention will be described in detail below. While specific embodiments of the invention are shown, it should be understood that the invention may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
It should be noted that certain terms are used throughout the description and claims to refer to particular components. Those of skill in the art will understand that a person may refer to the same component by different names. The specification and claims do not identify differences in terms of components, but rather differences in terms of the functionality of the components. As referred to throughout the specification and claims, the terms "include" or "comprising" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. The description hereinafter sets forth a preferred embodiment for practicing the invention, but is not intended to limit the scope of the invention, as the description proceeds with reference to the general principles of the description. The scope of the invention is defined by the appended claims.
The invention provides a composition for scalp care after hair implantation, which comprises an exendin substance.
The ectoin is derived from high-halophilic bacteria, has good anti-inflammatory repair effect, can structure free water in cells, continuously improve the moisture retention and water retention capability of throat, relieve dryness caused by pharyngitis, and can effectively improve the immunity protection capability of cells, enhance the cell repair capability and enable skin to effectively resist invasion of microorganisms and allergens.
The inventor finds that the exendin substance has the functions of resisting inflammation and moisturizing and also has the function of improving the survival rate of hair follicles in the research process, so that the exendin substance is suitable for scalp care after hair implantation.
In one embodiment, the ectoin is 0.05-5%, preferably 0.9-3.2% by mass of the composition.
For example, the exendin-based material may be 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, etc., based on the mass percent of the composition.
In one embodiment, the exenatide is exenatide and/or an exenatide derivative, preferably, the exenatide derivative is hydroxy exenatide, exenatide sodium salt and/or exenatide potassium salt.
In one embodiment, the composition further comprises a hyaluronan, preferably the hyaluronan is hyaluronic acid and/or hyaluronate, further preferably the hyaluronic acid and/or hyaluronate is 0.1-0.8%, preferably 0.3-0.6% by mass of the composition.
For example, the hyaluronic acid and/or hyaluronate may be 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, etc., by mass percent of the composition.
In one embodiment, the hyaluronate is selected from one or more of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate, and calcium hyaluronate, preferably sodium hyaluronate.
In one embodiment, the hyaluronan is a hyaluronan oligosaccharide, preferably having a molecular weight of 2500-9500Da, preferably 4000-6000Da.
The hyaluronic acid oligosaccharide substance refers to a hyaluronic acid molecular fragment with the relative molecular mass less than 10000Da and the monosaccharide residue number of 2-40 (generally 4-16), and belongs to small molecular polysaccharide.
For example, the molecular weight of the hyaluronic acid may be 2500Da, 3000Da, 3500Da, 4000Da, 4500Da, 5000Da, 5500Da, 6000Da, 6500Da, 7000Da, 7500Da, 8000Da, 8500Da, 9000Da, 9500Da, and the like.
The composition contains the hyaluronic acid substances, so that the composition can quickly permeate into scalp, and has the effects of resisting inflammation, preserving moisture, repairing damaged scalp angiogenesis and healing wounds.
In one embodiment, the composition further comprises a lysate of a fermentation product of Saccharomyces cerevisiae, preferably 0.01-0.5%, preferably 0.1-0.3% by mass of the composition.
The lysate of the fermentation product of the saccharomyces cerevisiae is a metabolite, a cytoplasmic fragment, a cell wall component and a polysaccharide complex which are obtained by culturing, inactivating and decomposing bifidobacteria, can improve the flora distribution on the surface of the skin, create an ideal living environment for probiotics, can indirectly inhibit the survival and propagation of harmful microorganisms, is easy to be absorbed by the skin, can quickly repair the damaged skin, and can improve the skin immunity.
For example, the lysate of the fermentation product of Saccharomyces cerevisiae may be 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, etc., by mass percent of the composition.
In one embodiment, the composition further comprises a plant extract having the effect of promoting wound healing and promoting hair follicle growth, thereby enhancing the efficacy of the composition and reducing the treatment time.
For the plant extract, it may be any single plant extract or mixed plant extract which is publicly used in the art and has a therapeutic effect on damaged scalp after hair planting, and preferably, the plant extract is a cocklebur fruit extract and/or a biota orientalis leaf extract.
Fructus Xanthii is a dry mature fruit with total bud of Xanthii fructus belonging to Compositae, has warm nature, pungent and bitter taste, has effects of dispelling pathogenic wind-cold, relieving stuffy nose, and dispelling pathogenic wind-dampness, and can be used for treating wind-cold headache, nasal obstruction, nasal discharge, and rubella pruritus. The fructus Xanthii and other plants belonging to the same genus have complex and various chemical components, mainly comprising terpenes, thiazines, thiophenes, glycosides, lignans and phenolic acid chemical components, and modern pharmacological researches prove that the fructus Xanthii ethanol extract has the effects of resisting inflammation, oxidization, viruses, proliferation, allergy and the like, the fructus Xanthii ethanol extract has stronger anti-inflammatory and analgesic effects, the pain caused by heat stimulation can be obviously relieved, and the flavonoid components in the ethanol extract have antibacterial activity.
The arborvitae twig has fragrant smell, bitter and astringent taste, enters lung, liver and spleen channels, has the effects of relieving cough, reducing phlegm, promoting hair growth and the like, and is suitable for various bleeding diseases. The cacumen biotae contains a plurality of medicinal active ingredients, wherein flavonoid, volatile oil and tannin are more studied, the cacumen biotae has a plurality of pharmacological effects of resisting bacteria, resisting tumors, stopping bleeding, promoting hair growth, resisting inflammation and the like, and modern pharmacological studies show that the cacumen biotae extract has better antibacterial activity in vitro and contains stronger anti-inflammatory ingredients, and the flavonoid ingredients in the extract can be used for treating alopecia, enhancing the activity of hair follicles, maintaining the normal growth of the hair follicles, inhibiting the hair follicles from entering the resting period from the growing period and delaying the alopecia.
In one embodiment, both the fructus Xanthii extract and the folium Platycladi extract are alcoholic extracts. The alcohol extract is not limited in any way, and can be purchased from the market or prepared according to the conventional technology in the art.
For example, the preparation method of the fructus xanthil extract comprises the following steps:
pulverizing fructus Xanthii into coarse powder, sieving with 40 mesh sieve, reflux extracting with 5 times of 95% ethanol twice for 2 hr each time, filtering, recovering ethanol from filtrate, adding 10 times of water, stirring, standing, and collecting oil layer to obtain fructus Xanthii extract.
The preparation method of the biota orientalis leaf extract comprises the following steps:
pulverizing folium Platycladi, sieving with 20 mesh sieve, adding 1 times of 50% ethanol solution, heating and reflux extracting for 3-4 hr, filtering while hot, concentrating the filtrate under reduced pressure with rotary evaporator to obtain extract, drying, and pulverizing into powder to obtain folium Platycladi extract.
In one embodiment, the fructus Xanthii extract is 0.5-2% and the folium Platycladi extract is 0.2% -1.8% by mass of the composition.
For example, the xanthium extract may be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0% and the like, by mass percent of the composition;
In one embodiment, the composition further comprises a pharmaceutically acceptable adjuvant, preferably, the pharmaceutically acceptable adjuvant is a surfactant.
The surfactant may be any of a variety of prior art reported, medically useful surfactants, such as tween-80 and the like. The amount of surfactant is selected and adjusted as desired.
In one embodiment, the composition comprises an exendin and a hyaluronic acid based on the weight percentage of the composition, the exendin being 0.05-5%, preferably 0.9-3.2%; the hyaluronic acid and/or hyaluronate is 0.1-0.8%, preferably 0.3-0.6%.
In one embodiment, the composition comprises an exendin and a hyaluronic acid based on the weight percentage of the composition, the exendin is 0.05-5%, preferably 0.9-3.2%; the hyaluronic acid and/or hyaluronate is 0.1-0.8%, preferably 0.3-0.6%, the exendin substance is one or more of exendin and/or exendin derivative, preferably, the exendin derivative is hydroxy exendin, exendin sodium salt and/or exendin potassium salt, the exendin substance is exendin and/or exendin derivative, preferably, the exendin derivative is hydroxy exendin, exendin sodium salt and/or exendin potassium salt, preferably, the hyaluronate is one or more of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate and calcium hyaluronate, preferably, sodium hyaluronate, preferably, the hyaluronic acid substance is hyaluronic acid oligosaccharide substance, preferably, the molecular weight of the hyaluronic acid substance is 2500-9500Da, preferably 4000-6000Da.
In one embodiment, the composition comprises a combination of a ricketiness material, a hyaluronic acid material and a lysate of a fermentation product of a saccharomyces cerevisiae, the ricketiness material being 0.05-5%, preferably 0.9-3.2% by mass of the composition; the hyaluronic acid and/or hyaluronate is 0.1-0.8%, preferably 0.3-0.6%; the lysate of the fermentation product of the saccharomyces cerevisiae is 0.01-0.5%, preferably 0.1-0.3%, preferably, the ectoine substance is ectoine and/or ectoine derivative, preferably, the ectoine derivative is hydroxy ectoine, ectoine sodium salt and/or ectoine potassium salt; preferably, the hyaluronic acid substance is hyaluronic acid and/or hyaluronate; the hyaluronate is one or more than two of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate and calcium hyaluronate, preferably sodium hyaluronate; the hyaluronic acid substance is hyaluronic acid oligosaccharide substance, preferably, the molecular weight of the hyaluronic acid substance is 2500-9500Da, preferably 4000-6000Da.
In one embodiment, the composition comprises a combination of a ricketiness substance, a hyaluronic acid, a lysate of a fermentation product of a bifenthrin and a plant extract, wherein the plant extract is a cocklebur fruit extract and/or a biota orientalis extract, and the ricketiness substance is 0.05-5%, preferably 0.9-3.2% by mass of the composition; the hyaluronic acid and/or hyaluronate is 0.1-0.8%, preferably 0.3-0.6%; the lysate of the fermentation product of the saccharomyces cerevisiae is 0.01-0.5%, preferably 0.1-0.3%; the fructus Xanthii extract is 0.5-2%, and the folium Platycladi extract is 0.2% -1.8%; preferably, the exemestane substance is exemestane and/or exemestane derivative, preferably, the exemestane derivative is hydroxy exemestane, exemestane sodium salt and/or exemestane potassium salt; preferably, the hyaluronic acid substance is hyaluronic acid and/or hyaluronate; the hyaluronate is one or more than two of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate and calcium hyaluronate, preferably sodium hyaluronate; the hyaluronic acid substance is hyaluronic acid oligosaccharide substance, preferably, the molecular weight of the hyaluronic acid substance is 2500-9500Da, preferably 4000-6000Da.
The composition provided by the invention can be used for repairing damaged scalp and hair follicles after hair implantation, promoting the survival rate of hair follicles after hair implantation, playing an anti-inflammatory role, reducing the incidence rate of folliculitis after hair implantation, accelerating wound healing and promoting skin healing.
The invention provides a preparation for scalp care after hair implantation, which is prepared from the raw materials of the composition.
The formulation may be in various forms, for example, spray, solution, drop, lotion, etc., preferably spray. The preparation methods of the various dosage forms and the selected excipients can be selected according to the disclosure in the prior art.
The invention provides a method for preparing a spray for scalp care after hair implantation, which comprises the following steps:
dissolving the exendin substance, optional hyaluronic acid substance and optional lysate of fermentation product of the two yeasts in water to obtain solution A;
adding an optional surfactant into the solution A to obtain a solution B;
adding the optional plant extract into solution B to obtain spray.
"optional" refers to a method of preparing a spray for post-plant scalp care that may or may not be present, for example, when hyaluronan, yeast lysate, surfactant, and plant extract are not present, comprising the steps of:
Dissolving the exendin substance in water to obtain the spray.
Similarly, the preparation is similar when other ingredients are not present.
The water may be water for injection.
In one embodiment, the exenatide is exenatide and/or an exenatide derivative, preferably, the exenatide derivative is hydroxy exenatide, exenatide sodium salt and/or exenatide potassium salt, and more preferably, the exenatide is 0.05-5%, preferably 0.9-3.2% based on the mass percentage in the spray.
In one embodiment, the hyaluronic acid substance is hyaluronic acid and/or hyaluronate, preferably, the hyaluronate is one or more than two of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate and calcium hyaluronate, preferably sodium hyaluronate, further preferably, the hyaluronic acid and/or hyaluronate is 0.1-0.8%, preferably 0.3-0.6% of the weight of the spray.
In one embodiment, the hyaluronan is a hyaluronan oligosaccharide, preferably having a molecular weight of 2500-9500Da, preferably 4000-6000Da.
In one embodiment, the lysate of the Saccharomyces cerevisiae fermentation product is 0.01-0.5%, preferably 0.1-0.3% by mass of the spray.
In one embodiment, the plant extract is a cocklebur fruit extract and/or a biota orientalis leaf extract; further preferably, the cocklebur fruit extract is 0.5-2% and the biota orientalis leaf extract is 0.2% -1.8% by mass percent of the spray.
The present invention provides the use of an exendin-type substance in a scalp care product, preferably in a scalp care product after hair implantation, more preferably in a scalp care product for increasing the survival rate of hair follicles.
The ectoine substance has the effects of resisting inflammation and preserving moisture and improving the survival rate of hair follicles, so that the ectoine substance can be used in the field of scalp care products after hair implantation to reduce the incidence rate of folliculitis after hair implantation, accelerate wound healing and promote skin healing.
In one embodiment, the ectoin is 0.05-5%, preferably 0.9-3.2% by mass of the scalp care product.
In one embodiment, the exenatide is exenatide and/or an exenatide derivative, preferably, the exenatide derivative is hydroxy exenatide, exenatide sodium salt and/or exenatide potassium salt.
The invention provides a scalp care product comprising the composition or the preparation.
In one embodiment, the scalp care product further comprises an adjunct.
The auxiliary materials are auxiliary materials commonly used in the field, and can be tween-80, glycerol, propylene glycol, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride and the like.
Examples
The materials used in the test and the test methods are described generally and/or specifically in the examples which follow,% represents wt%, i.e. weight percent, unless otherwise specified. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge.
Example 1
The ectoin is dissolved in water for injection to obtain a spray, wherein the content of the ectoin is 5%.
Example 2
The ectoin is dissolved in water for injection to obtain a spray, wherein the content of the ectoin is 0.05%.
Example 3
The ectoin is dissolved in water for injection to obtain a spray, wherein the content of the ectoin is 2%.
Example 4
The content of the exendin is 2% and the content of the sodium hyaluronate is 0.1% are dissolved in water for injection to obtain a spray.
Example 5
Sodium hyaluronate (molecular weight 9500 Da) was dissolved in water for injection to obtain a spray, wherein the content of sodium hyaluronate was 0.1%.
Example 6
Dissolving the lysate of the fermentation product of the saccharomyces cerevisiae in water for injection to obtain the spray, wherein the content of the lysate of the fermentation product of the saccharomyces cerevisiae is 0.5 percent.
Example 7
And dissolving the ectoin and the lysate of the fermentation product of the two yeasts in water for injection to obtain the spray, wherein the content of the ectoin is 2%, and the lysate of the fermentation product of the two yeasts is 0.5%.
Example 8
The ectoine, sodium hyaluronate (molecular weight is 9500 Da) and the lysate of the fermentation product of the saccharomyces cerevisiae are dissolved in water for injection to obtain a spray, wherein the content of the ectoine is 2%, the sodium hyaluronate is 0.1%, and the content of the lysate of the fermentation product of the saccharomyces cerevisiae is 0.5%.
Example 9
(1) Dissolving sodium hyaluronate (molecular weight of 9500 Da), ectoin, and yeast fermentation product lysate in water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.1%, the content of ectoin is 5%, the content of lysate of two-part yeast fermentation product is 0.01%, the content of fructus Xanthii extract is 1.0%, the content of folium Platycladi extract is 0.8%, and the content of tween-80 is 2.0%.
Example 10
(1) Dissolving sodium hyaluronate (molecular weight is 3000 Da), ectoin, and yeast fermentation product lysate of two cracks in water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.78%, the content of ectoin is 0.05%, the content of lysate of fermentation product of two-part yeast is 0.5%, the content of fructus Xanthii extract is 1.5%, the content of folium Platycladi extract is 1.2%, and the content of tween-80 is 2.0%.
Example 11
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 12
(1) Dissolving potassium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 13
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), hydroxyectoin, and lysate of fermentation product of two-split yeast in water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 14
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da) and ectoin in water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 15
(1) Dissolving the lysate of the fermentation product of the ectoin and the saccharomyces cerevisiae in water for injection to obtain a solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 16
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.5%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 17
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.1%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 18
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.3%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 19
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 5%, the content of lysate of two-part yeast fermentation product is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 20
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 2%, the content of lysate of two-part yeast fermentation product is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 21
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of ectoin is 3.2%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 22
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.78%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 23
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.1%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 24
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.3%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 25
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da), ectoin and yeast fermentation product lysate into water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.6%, the content of ectoin is 0.9%, the content of lysate of fermentation product of two-part yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Example 26
Dissolving sodium hyaluronate (molecular weight of 5000 Da), ectoin, and yeast fermentation product lysate in injectable water to obtain spray;
Wherein, the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, and the content of lysate of fermentation product of two-split yeast is 0.3%.
Example 27
Dissolving sodium hyaluronate (molecular weight 4000 Da), ectoin, and yeast fermentation product lysate into injectable water to obtain spray;
wherein, the content of sodium hyaluronate is 0.55%, the content of ectoin is 0.9%, and the content of lysate of fermentation product of two-split yeast is 0.1%.
Example 28
Dissolving sodium hyaluronate (molecular weight is 6000 Da), ectoin, and yeast fermentation product lysate in injectable water to obtain spray;
wherein, the content of sodium hyaluronate is 0.3%, the content of ectoin is 3.2%, and the content of lysate of fermentation product of two-split yeast is 0.2%.
Comparative example 1
(1) Dissolving sodium hyaluronate (molecular weight is 5000 Da) and lysate of fermentation product of Saccharomyces cerevisiae in water for injection to obtain solution A;
(2) Adding tween-80 into the solution A, and uniformly stirring to obtain a solution B;
(3) Adding folium Platycladi extract into fructus Xanthii extract, and adding into solution B under stirring to obtain spray, wherein the content of sodium hyaluronate is 0.55%, the content of lysate of fermentation product of two-stage yeast is 0.23%, the content of fructus Xanthii extract is 1.1%, the content of folium Platycladi extract is 1.5%, and the content of tween-80 is 2.0%.
Comparative example 2
Physiological saline containing 0.9% medical grade sodium chloride
Table 1 table of amounts of components used in examples and comparative examples
Experimental example 1 evaluation of proliferation effect of papilla cells
Taking human hair papilla cell HDP (Qingqi (Shanghai) Biotechnology development Co., ltd.) in logarithmic growth phase, inoculating into 96-well plate at appropriate density, each 100 μl, adding 10% foetal calf serum into DMEM high sugar culture solution, placing the inoculated cells into carbon dioxide incubator at 37deg.C and 5% CO 2 Culturing for 24h conventionally. The samples of each example and comparative example were diluted to 20% concentration in serum-free medium and sterilized by filtration through a 0.22 μm filter. After the cells were routinely cultured for 24 hours, the old culture solution was discarded, the test group (example and comparative example) was replaced with 100. Mu.L of the sample, the negative control group was added with the same amount of the culture solution, the sample solution was discarded after further culturing for 24 hours, 10% WST-1 solution prepared with serum-free culture solution was added to each well, and the culture was continued in a cell incubator for 3 hours, and absorbance was measured at a wavelength of 450nm with an enzyme-labeled instrument (Infinite, diken China), wherein the relative increment rate (RGR) was the ratio of the absorbance of the test group to the absorbance of the negative control group, and the results are shown in Table 2.
TABLE 2 statistics of proliferation promoting effect of products of examples and comparative examples on papilla cells
From the above table, the scalp care spray can obviously promote proliferation of hair papilla cells after hair implantation.
Experimental example 3 evaluation of anti-inflammatory Effect
HaCaT cells (human immortalized epidermal cells, qingqi (Shanghai) Biotechnology development Co., ltd.) with good growth state are inoculated into a 96-well plate and placed in a cell incubator at 37 ℃ for culture. After 24h of cell plating, 1 μg/ml of LPS (lipopolysaccharide, sigma-Aldrich) was added to stimulate the production of inflammatory factors, each sample was added after molding was successful, each group of cell culture supernatants was collected after 24h, and centrifuged at 4000r/min for 5 minutes, the obtained cell supernatants were used in ELISA test, and the levels of TNF- α and IL-1 α cytokines were detected by ELISA kit (Siemedas), and the specific procedures were performed according to the kit instructions, and the results are shown in Table 3.
Table 3 statistics of anti-inflammatory effects of each example and comparative example products
From the above table, the concentrations of TNF-alpha and IL-1 alpha in LPS molding groups were significantly higher than those in the blank group, indicating that LPS molding was successful. Analysis of the data shows that the inflammatory factors in the example group are obviously reduced compared with the LPS (LPS) model, which proves that the spray provided by the invention has a better inhibiting effect on the inflammatory factors.
In conclusion, the composition disclosed by the invention can repair injured scalp and hair follicles after hair implantation, promote the survival rate of hair follicles after hair implantation, obviously promote proliferation of hair papilla cells, and has a good inhibition effect on inflammatory factors.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the invention in any way, and any person skilled in the art may make modifications or alterations to the disclosed technical content to the equivalent embodiments. However, any simple modification, equivalent variation and variation of the above embodiments according to the technical substance of the present invention still fall within the protection scope of the technical solution of the present invention.
Claims (10)
1. A composition for scalp care after hair implantation comprising an exemestane species.
2. Composition according to claim 1, wherein the ectoin substance is 0.05-5%, preferably 0.9-3.2% by mass of the composition.
3. Composition according to claim 1 or 2, wherein the exemestane is exemestane and/or an exemestane derivative, preferably the exemestane derivative is hydroxyexemestane, exemestane sodium salt and/or exemestane potassium salt;
preferably, the composition further comprises hyaluronic acid substances, preferably, the hyaluronic acid substances are hyaluronic acid and/or hyaluronate, and further preferably, the hyaluronic acid and/or hyaluronate accounts for 0.1-0.8%, preferably 0.3-0.6% of the composition by mass percent;
Preferably, the hyaluronate is one or more selected from sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate and calcium hyaluronate, preferably sodium hyaluronate.
4. A composition according to claim 3, wherein the hyaluronan is a hyaluronan oligosaccharide, preferably having a molecular weight of 2500-9500Da, preferably 4000-6000Da;
preferably, the composition further comprises a lysate of a fermentation product of Saccharomyces cerevisiae, preferably, the lysate of a fermentation product of Saccharomyces cerevisiae is 0.01-0.5%, preferably 0.1-0.3% by mass of the composition;
preferably, the composition further comprises a plant extract, preferably, the plant extract is an extract of Xanthium sibiricum and/or an extract of Platycladus orientalis; further preferably, the fructus Xanthii extract is 0.5-2% and the cacumen Platycladi extract is 0.2% -1.8% by mass of the composition;
preferably, the composition further comprises a pharmaceutically acceptable adjuvant, preferably a surfactant.
5. A formulation for scalp care after hair implantation, the formulation being made from the materials of the composition of any one of claims 1-4;
Preferably, the formulation is in the form of a solution, spray, drop or lotion, preferably a spray.
6. A method of preparing a spray for post-hair-implantation scalp care comprising the steps of:
dissolving the exendin substance, optional hyaluronic acid substance and optional lysate of fermentation product of the two yeasts in water to obtain solution A;
adding an optional surfactant into the solution A to obtain a solution B;
adding the optional plant extract into solution B to obtain spray.
7. The method according to claim 6, wherein the exemestane is exemestane and/or an exemestane derivative, preferably, the exemestane derivative is hydroxy exemestane, exemestane sodium salt and/or exemestane salt, more preferably, the exemestane is 0.05-5%, preferably 0.9-3.2% based on the mass percentage of the spray.
8. The method according to claim 6 or 7, wherein the hyaluronic acid substance is hyaluronic acid and/or hyaluronate, preferably, the hyaluronate is one or more selected from sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, magnesium hyaluronate and calcium hyaluronate, preferably sodium hyaluronate, further preferably, the hyaluronic acid and/or hyaluronate is 0.1-0.8%, preferably 0.3-0.6% by mass percentage in the spray;
Preferably, the hyaluronic acid substance is hyaluronic acid oligosaccharide substance, preferably, the molecular weight of the hyaluronic acid substance is 2500-9500Da, preferably 4000-6000Da;
preferably, the lysate of the fermentation product of the saccharomyces cerevisiae is 0.01-0.5%, preferably 0.1-0.3% by mass percent of the aerosol;
preferably, the plant extract is fructus Xanthii extract and/or folium Platycladi extract; further preferably, the cocklebur fruit extract is 0.5-2% and the biota orientalis leaf extract is 0.2% -1.8% by mass percent of the spray.
9. The use of an exemestane in a scalp care product, preferably in a scalp care product after hair implantation, more preferably in a scalp care product for increasing the survival rate of hair follicles;
preferably, the ectoin substance is 0.05-5%, preferably 0.9-3.2% by mass of the scalp care product;
preferably, the exemestane is exemestane and/or exemestane derivative, preferably, the exemestane derivative is hydroxy exemestane, exemestane sodium salt and/or exemestane potassium salt.
10. A scalp care comprising the composition of any one of claims 1-4 or the formulation of claim 5;
preferably, the scalp care product further comprises an auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111512463.2A CN116236425A (en) | 2021-12-07 | 2021-12-07 | Composition for scalp care after hair implantation, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111512463.2A CN116236425A (en) | 2021-12-07 | 2021-12-07 | Composition for scalp care after hair implantation, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116236425A true CN116236425A (en) | 2023-06-09 |
Family
ID=86631841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111512463.2A Pending CN116236425A (en) | 2021-12-07 | 2021-12-07 | Composition for scalp care after hair implantation, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116236425A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003047539A2 (en) * | 2001-12-05 | 2003-06-12 | Henkel Kommanditgesellschaft Auf Aktien | Use of ectoin and ectoin derivatives for the treatment of hair |
| WO2018207952A1 (en) * | 2017-05-12 | 2018-11-15 | 国立大学法人九州大学 | Composition for hair growth and/or hair restoration |
| CN110585478A (en) * | 2019-08-23 | 2019-12-20 | 镇江大美瑞珍麦迪森生物技术有限公司 | Hair-planting restoration liquid and preparation method thereof |
| CN112656709A (en) * | 2021-01-06 | 2021-04-16 | 华熙生物科技股份有限公司 | Skin care compositions and uses thereof |
| CN113018246A (en) * | 2021-03-16 | 2021-06-25 | 广东格物生物科技有限公司 | Probiotic shampoo capable of relieving scalp inflammation and preparation method thereof |
| CN113304065A (en) * | 2021-05-08 | 2021-08-27 | 广州宝思利生物科技有限公司 | Scalp care composition and application thereof |
| CN113456514A (en) * | 2021-08-16 | 2021-10-01 | 华熙生物科技股份有限公司 | Scalp care composition containing hyaluronic acid and preparation method and application thereof |
-
2021
- 2021-12-07 CN CN202111512463.2A patent/CN116236425A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003047539A2 (en) * | 2001-12-05 | 2003-06-12 | Henkel Kommanditgesellschaft Auf Aktien | Use of ectoin and ectoin derivatives for the treatment of hair |
| WO2018207952A1 (en) * | 2017-05-12 | 2018-11-15 | 国立大学法人九州大学 | Composition for hair growth and/or hair restoration |
| CN110585478A (en) * | 2019-08-23 | 2019-12-20 | 镇江大美瑞珍麦迪森生物技术有限公司 | Hair-planting restoration liquid and preparation method thereof |
| CN112656709A (en) * | 2021-01-06 | 2021-04-16 | 华熙生物科技股份有限公司 | Skin care compositions and uses thereof |
| CN113018246A (en) * | 2021-03-16 | 2021-06-25 | 广东格物生物科技有限公司 | Probiotic shampoo capable of relieving scalp inflammation and preparation method thereof |
| CN113304065A (en) * | 2021-05-08 | 2021-08-27 | 广州宝思利生物科技有限公司 | Scalp care composition and application thereof |
| CN113456514A (en) * | 2021-08-16 | 2021-10-01 | 华熙生物科技股份有限公司 | Scalp care composition containing hyaluronic acid and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107669564B (en) | Skin care composition with functions of repairing and regenerating, moisturizing and delaying senescence | |
| Asif et al. | Wound healing activity of root extracts of Berberis lyceum Royle in rats | |
| CN111956860B (en) | Liquid trehalose dressing for repairing skin barrier wound surface and preparation method thereof | |
| US20120328721A1 (en) | Aloe vera sprout concentrate or extract having superior skin cell growth promotion, antioxidant, and anti-allergy effects | |
| CN111529470B (en) | Compound acne-removing and allergy-relieving gel and preparation method thereof | |
| CN114712440A (en) | Dai medicine composition for relieving senile cutaneous pruritus and preparation and application thereof | |
| CN113520896A (en) | Composition with acne removing and acne mark repairing functions and preparation method thereof | |
| CN116236425A (en) | Composition for scalp care after hair implantation, preparation method and application thereof | |
| CN113616774B (en) | Antibacterial composition containing plant stem cells, maintenance antibacterial liquid and preparation method thereof | |
| CN112274548B (en) | External composition with wound healing effect and preparation method and application thereof | |
| CN111939191B (en) | Composition for promoting angiogenesis around hair follicle and/or promoting hair growth and application | |
| KR102054100B1 (en) | Cosmetic composition containing fermented extract of roots | |
| KR101969983B1 (en) | Shampoo composition for improving hair loss containing soil-board salt and method the same | |
| CN112043650A (en) | Acne-removing repairing cosmetic preparation and preparation method thereof | |
| CN105168091A (en) | Telangiectasis removing mask powder and preparation method thereof | |
| CN116077567B (en) | Hypericum perforatum wound healing promoting pharmaceutical composition and preparation method and application thereof | |
| KR102526210B1 (en) | Composition for improving skin regeneration and wound-healing comprising fermented Mastic Gum extract and method for manufacturing the same | |
| CN102357145A (en) | Externally applied ointment for treating baldness | |
| KR102168418B1 (en) | Feminine Cleanser Composition Comprising Combined Extracts of Dendropanax morbifera Lev, Astragalus membranaceus and Aralia elata | |
| CN108186737B (en) | External drop for treating paronychia and preparation method thereof | |
| CN104856918A (en) | Aloe-containing beauty mask and preparation method thereof | |
| RU2418605C1 (en) | Method of treating respiratory diseases in calves | |
| KR101922488B1 (en) | A composition for treating and preventing hair loss containing pozzolan, Sappan wood extract and siegesbockia herb extract | |
| CN115957292A (en) | Anti-hair loss composite spray containing finasteride | |
| KR20150135757A (en) | Composition for promoting the volume of skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |